ALK and non-small cell lung carcinoma: Interestingly, similar to the outcomes observed in EGFR-mutated NSCLC, the IMpower150 trial reported encouraging signals with the combination of chemotherapy, immunotherapy, and bevacizumab in ALK-rearranged tumors [93].